Abeona Therapeutics Annual Revenue, Competitors, Number of Employees and Funding

Claim your profile

Overview

Location:
Total Funding:$12.9M
Industry:Biotech
Founded:2015
Lead Investor(s):Jefferies LLC
Press
Claim your profile

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Abeona Therapeutics's estimated annual revenue is currently $5.3M per year.
  • Abeona Therapeutics received $92.0M in venture funding in October 2017.
  • Abeona Therapeutics's estimated revenue per employee is $62,824
  • Abeona Therapeutics's total funding is $12.9M.

Employee Data

  • Abeona Therapeutics has 85 Employees.
  • Abeona Therapeutics grew their employee count by -2% last year.
  • Abeona Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Brainstorm Cell...
N/A21N/AN/A
Empire Genomics...
N/A29N/AN/A
North Central B...
$41.2M2665%N/A
Enzo Biochem
N/A32N/AN/A
Axsome Therapeu...
$4.8M330%N/A
Progenics Pharm...
$20M12915%N/A
Regeneron Pharm...
N/A8323N/AN/A
Sartorius Stedi...
$16.7M10826%N/A
Outlook Therape...
$6.8M44100%N/A
Envisagenics
$2.6M17N/AN/A
Missing a competitor? Contribute!?
Submit

Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

85

Number of Employees

$5.3M

Revenue (est)

1

Current Jobs

-2%

Employee Growth %

$12.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
James BircherSVP Quality and Technical OperationsEmail Available
Aleixo SantiagoDirectorEmail Available
Scott SantiamoDirector Corporate CommunicationsEmail Available
Edward SturchioSenior Vice President, General Counsel and Corporate SecretaryEmail Available
Sarah HirschClinical Trial ManagerEmail Available
Jaime FensterlAssociate DirectorEmail Available
Michael SnyderSenior Director ClinicalEmail Available
Aaron CardinalSenior Manager, ValidationEmail Available
Andre'a Andre'a LuccaVice President,Communications & OperationsEmail Available
Kari HensonProgram Manager, Gene & Cell Therapy ProgramsEmail Available

Abeona Therapeutics News

09/03/2019 - Abeona Therapeutics Announces Strategic Review

NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...

09/03/2019 - Abeona Therapeutics (ABEO) Announces Strategic Review

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies ...

08/09/2019 - Abeona Therapeutics Reports Second Quarter 2019 Financial ...

NEW YORK and CLEVELAND, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...

Abeona Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-12-17$0.8MUndisclosedMultipleArticle
2014-12-02$3.6MUndisclosedMultipleArticle
2015-07-30$8.5MUndisclosedArticle
2017-10-18$92.0MUndisclosedJefferies LLCArticle

Abeona Therapeutics Executive Hires

DateNameTitleReference
2017-07-26Juan RuizChief Medical OfficerArticle
2018-04-03Carsten ThielChief Executive OfficerArticle
2018-10-22João SiffertHead of Research and Development and Chief Medical OfficerArticle
2019-02-12João SiffertCEOArticle

Abeona Therapeutics New Location/Offices

DateLocationReference
2018-06-06Columbus, OHArticle